Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mayo

Showing results (341-350 of 375) with videos related to

Pageof 38
Sort By:
Frontiers in Immunology|April 16, 2014
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosisCarlo Selmi, Francesca Cavaciocchi, Ana Lleo, et al.
Gut|December 18, 2019
Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitisMaren H Harms, Rozanne C de Veer, Willem J Lammers, et al.
The New England Journal of Medicine|February 21, 2024
A Phase 3 Trial of Seladelpar in Primary Biliary CholangitisGideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, et al.
The American Journal of Gastroenterology|December 13, 2017
Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and OutcomeMaren H Harms, Willem J Lammers, Douglas Thorburn, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 24, 2020
Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study GroupSamantha J Mayo, Maryam Lustberg, Haryana M Dhillon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 17, 2019
Factors Associated With Progression and Outcomes of Early Stage Primary Biliary CholangitisNikolaos K Gatselis, Jorn C Goet, Kalliopi Zachou, et al.
Gastroenterology|August 12, 2015
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid TherapyWillem J Lammers, Gideon M Hirschfield, Christophe Corpechot, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Alimentary Pharmacology & Therapeutics|October 18, 2019
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment responseCarla F Murillo Perez, Gideon M Hirschfield, Christophe Corpechot, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
Pageof 38

Showing results (341-350 of 375) with videos related to

Sort By:
Pageof 38
Frontiers in Immunology|April 16, 2014
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosisCarlo Selmi, Francesca Cavaciocchi, Ana Lleo, et al.
Gut|December 18, 2019
Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitisMaren H Harms, Rozanne C de Veer, Willem J Lammers, et al.
The New England Journal of Medicine|February 21, 2024
A Phase 3 Trial of Seladelpar in Primary Biliary CholangitisGideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, et al.
The American Journal of Gastroenterology|December 13, 2017
Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and OutcomeMaren H Harms, Willem J Lammers, Douglas Thorburn, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 24, 2020
Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study GroupSamantha J Mayo, Maryam Lustberg, Haryana M Dhillon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 17, 2019
Factors Associated With Progression and Outcomes of Early Stage Primary Biliary CholangitisNikolaos K Gatselis, Jorn C Goet, Kalliopi Zachou, et al.
Gastroenterology|August 12, 2015
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid TherapyWillem J Lammers, Gideon M Hirschfield, Christophe Corpechot, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Alimentary Pharmacology & Therapeutics|October 18, 2019
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment responseCarla F Murillo Perez, Gideon M Hirschfield, Christophe Corpechot, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
Pageof 38